学术讲座－医学院

报告题目：Cancer virotherapy and immunotherapy
– from bench to bedside
报告人：  Xiaoliu Zhang博士
时  间：    2008年6月5日（星期四） 15:30
地  点：    医学院408室
 
主办单位：       暨南大学医学院血液病研究所
广东省抗癌协会血液肿瘤专业委员会
 
 
欢迎有兴趣的老师和同学参加!
 
 
Xiaoliu Zhang博士简介：
 
Associate Professor, Departments of Pediatrics, Molecular Virology and Microbiology 
Principle Investigator, HSV Laboratory, Center for Cell and Gene Therapy,
Baylor College of Medicine
 
Educational Background：
1978-1983             M.B.  Wuhan Medical College, Wuhan, China.
1983-1986             M.D.  Tongji Medical University, Wuhan, China
1983-1987             Ph.D.  Australian National University, Canberra, Australia.
Professional Experience:
2005 – present        Associate Professor, Department of Pediatrics, Baylor College of  Medicine, Houston, Texas.
1999 – Present         Adjunct Associate Professor, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.
1999 – Present         Faculty Member, Center for Cell and Gene Therapy, Baylor College oMedicine, Houston, Texas
Professional societies：
American Society of Gene Therapy
American Society of Association for the Advancement of Science
 
National and international scientific participations:
1996 – present:  Reviewer for professional journals including: Blood, Cancer Research, Human Gene Therapy, Molecular Therapy, Gene Therapy & Molecular Biology, Clinical Cancer Research, Gene Therapy, Nature Biotechnology, Future Oncology
Research support:
1. NIH (Zhang)                                                                   
Title: Strategies to Enhance Virotherapy for Breast Cancer                    
2. Owens Foundation                                     
Title: Treatment of pancreatic cancer with fusogenic oncolytic virus.
3. Industry Sponsored Research (by Immusol, Inc.)             
Title: Development of an HSV-2-based oncolytic virus
      
Intellectual property:
1.  S. Efstathiou, S. Inglis and X. Zhang. VECTORS FOR GENE DELIVERY (granted). US Patent No. 5,928,913
2.  X. Zhang and X. Fu. Potent Oncolytic Herpes Simplex Virus for Cancer Therapy (pending). U.S. Patent Application No. 10/397,635
3.  X. Zhang and X. Fu. MUTANT HERPES SIMPLEX VIRUS-2 FOR CANCER THERAPY (PENDING). 2005. P03196US0
 
Publications(within 5 years )
1.      X. Fu, L. Tao, A. Jin, R. Vile, M.K. Brenner and X. Zhang (2003).  Expression of fusogenic membrane glycoprotein by an oncolytic herpes simplex virus provides potent synergistic anti-tumor effect. Mol. Ther. 7(6): 748-54.
2.      X. Fu, L. Tao and X. Zhang (2003). The promoter of the strictly late viral gene UL38 is a tumor specific in the context of an oncolytic herpes simplex virus. Gene Ther. 10(17): 1458-1464.
3.      Nakamori, M. Fu, X. Meng, F. Jin, A. Bast, R and X. Zhang (2003). Enhanced therapy of metastatic ovarian cancer with a double fusion oncolytic herpes simplex virus. Clin. Cancer Res. 9(7): 2727-2733.
4.      M. Nakamori, Iwahashi M, Ueda K, Tsunoda T, Nakamura M, Hamada H, Zhang X. and Yamaue H (2003). Intensification of antitumor effect by T helper 1-dominant adoptive immunogene therapy for advanced orthotopic colon cancer. Clin. Cancer Res. 9(6): 2357-2365.
5.      Mikihito Nakamori, Xinping Fu, Curtis A. Pettaway and Xiaoliu Zhang (2004). Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. The Prostate. 60(1): 53-60.
6.      Mikihito Nakamori, Xinping Fu, Raphael Rousseau, Si-Yi Chen and Xiaoliu Zhang (2004). Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol. Ther. 9(5): 658-665.
7.      C. Lee, X. Liu, C. Smith, X. Zhang, H. Hsu, D. Wang and Z. Luo (2004). The combined regulation of estrogen and cyclic tension on fibroblast biosynthesis derived from anterior cruciate ligament. Matrix Bio. 23: 323-329.
8.      C.Y. Lee, C. Smith, X. Zhang, H. Hsu, D. Wang and Z. Luo (2004). Tensile forces attenuate estrogen-stimulated collagen synthesis in the ACL. Biochem Biophys Res Commun. 317(4): 1221-1225.
9.      Xuhui Liu,  Xiaoliu Zhang,  Zong-Ping Luo (2005). Strain-related collagen gene expression in human osteoblast-like cells. Cell Tissue Res. 17; 1-4.
10.  X. Fu, M. Nakamori and X. Zhang. (2005). Fusogenic Oncolytic Herpes Simplex Virus. In: Virus Therapy of Human Cancers. Sinkovics & Horvath eds. (New York: marcel dekker Inc.) pp713-738.
11.  Min Li; Joel A. Rodriguez; William E. Fisher; Xiaoliu Zhang; Changyi Chen ; Qizhi Yao (2006). Viral Vectors in Pancreatic Cancer Gene Therapy. Gene Therapy & Molecular Biology, 10: 61-70.
12.  Fu X, Tao L, Prigge J, Cai R, Zhang X. (2006). A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Mol. Ther. 13(5): 882-890.
13.  Xinping Fu, Lihua Tao, Min L, William E. Fisher and Xiaoliu Zhang (2006) Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus. Clin. Cancer Res. 12(10): 3152-3157.
14.  Hongtao Li, Aurelie Dutuor, Lihua Tao, Xinping Fu and Xiaoliu Zhang (2007). Virotherapy with an HSV-2-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. 2006. Clin. Cancer Res. 13(1): 316-322.
15.  Hongtao Li, Aurelie Dutuor, Xinping Fu and Xiaoliu Zhang (2007). Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model. Journal of Gene Medicine. 9(3): 161-169.
16.  Xinping Fu, Lihua Tao and Xiaoliu Zhang (2007). A novel oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Therapy. 14: 480-487.
17.  Xinping Fu, Lihua Tao, Robert Amato and Xiaoliu Zhang (2007). Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma. International Journal of Oncology. 30(6): 1561-1567.
18.  Xinping Fu, Lihua Tao, Xiaoliu Zhang (2007). An HSV-2-based oncolytic virus deleted in the PK domain of the ICP10 gene is a potent inducer of apoptotic death in tumor cells. Gene Therapy. 14(12): 1-8.
19.  Hontao Li, Zihua Zeng, Xinping Fu and Xiaoliu Zhang (2007). Co-administration of an HSV-2-based oncolytic virus with cyclophosphamide leads to synergistic antitumor effect and induction of tumor-specific immune responses in the Lewis Lung tumor model. Cancer Res. 67, 7850-7855.
20.  X. Fu, C. Ma, C. Strathdee, and X. Zhang (2007). De Novo Synthesis of Circular Form Viral Genome During Lytic HSV-1. J. Gen. Virol. Revised.
 
作者：李晶